TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01905462

Intervention type: OTHER
Intervention: Data Collection
Description: Analyses of data collected within the CPRD GOLD database.

Intervention type: OTHER
Intervention: Data Collection
Description: Analyses of data collected within the CPRD GOLD database.

Intervention type: BIOLOGICAL
Intervention: Cervarix
Description: Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.

Intervention type: BIOLOGICAL
Intervention: Cervarix
Description: Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
Study: NCT01296646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg oral naltrexone once/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg oral naltrexone once/day
Study: NCT01061840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™
Description: Patients will be treated once a month as long as sufficient material is available for up to 12 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil™
Description: Patients will be treated once a month as long as sufficient material is available for up to 12 doses
Study: NCT01296646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg oral naltrexone once/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg oral naltrexone once/day

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brenda Therapy Sessions
Description: participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brenda Therapy Sessions
Description: participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brenda Therapy Sessions
Description: participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brenda Therapy Sessions
Description: participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: An inactive pill to control for non-pharmacological responses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: An inactive pill to control for non-pharmacological responses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: An inactive pill to control for non-pharmacological responses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: An inactive pill to control for non-pharmacological responses.
Study: NCT00209742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFT
Description: P.O. everyday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT
Description: P.O. everyday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT
Description: P.O. everyday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: USEL/Leucovorin
Description: P.O. everyday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USEL/Leucovorin
Description: P.O. everyday
Study: NCT01833390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HXe MRI lung ventilation
Description: MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
Study: NCT03638518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
Study: NCT02774668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grab-and-Go meal plan
Description: The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jump-Start meal plan
Description: The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ.
Study: NCT00835276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg tablets
Description: 1 x 180 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALLEGRA® 180 mg tablets
Description: 1 x 180 mg
Study: NCT02126241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICaS guided CRT optimization
Description: 1. Baseline CO measurement by NICaS~2. AV delay optimization:~   1. AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~  2. The AV delay yielding the maximal CO, will be considered the optimal AV delay~  3. The device will be programmed using the optimal AV delay~3. VV delay optimization:~   1. After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~  2. The VV delay yielding the maximal CO, will be considered the optimal VV delay~  3. The device will be programmed using the optimal VV delay
Study: NCT03304093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Nivolumab 3mg/kg every 2 weeks
Study: NCT00776191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physioneal 35
Description: Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physioneal 40
Description: Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
Study: NCT00584779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: CLcr:14-5 mL/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: CLcr: 29-15 mL/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Hemodialysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: CLcr: 29-30 mL/min
Study: NCT01405027

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Educational Intervention
Description: Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.

Intervention type: OTHER
Group type: OTHER
Intervention: Patient education and management skills training
Description: Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
Study: NCT02089867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ezetimibe + plant sterols
Description: The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols
Description: The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
Study: NCT02359136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local infiltration anesthesia using Ropivacaine and Epinephrine
Description: 150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
Study: NCT02272062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision-making tool for coronary artery disease treatment
Description: A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
Study: NCT02359136

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: local infiltration anesthesia using saline
Description: 150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic regimen
Description: All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal analgesic regimen
Description: All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
Study: NCT01462045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based exercise
Description: 8-week program of mindfulness-based stretching and breathing exercises
Study: NCT03436745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
Study: NCT02488356

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litramine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Litramine
Study: NCT01951911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03855761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Detailed narrative assessment and person-centered participation in meaningful activities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management; psychological services
Description: Weekly consultation with case managers to address housing and therapy needs
Study: NCT01948518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sildenafil 20 mg
Description: A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
Study: NCT00949806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT (intradermal injection)
Description: Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient.
Study: NCT03955120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dayzz mobile sleep training
Description: 1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dayzz mobile sleep training
Description: 1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard medical care for specific sleep condition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard medical care for specific sleep condition
Study: NCT02283333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BATE-G
Description: Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
Study: NCT04350372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip Procedure
Description: MitraClip procedure with MitraClip NT System
Study: NCT02792036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxitrol®
Description: Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Therapy
Description: Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaque Radiotherapy
Description: Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
Study: NCT04067440

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbial Swab
Description: Swabs will be taken from peritoneum and jejunum (intraoperatively), rectum, and stool
Study: NCT00209742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USEL/Leucovorin
Description: P.O. everyday
Study: NCT00388375

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Ultrasound
Description: limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
Study: NCT00209742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin
Description: P.O. everyday
Study: NCT01656018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278, Long acting (LA)
Description: TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
Study: NCT02607033

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
Study: NCT00525330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104 QD Drug: Placebo Drug: Metformin
Description: KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug: Metformin
Description: Two tablets 15 to 30 minutes before each meal, morning and evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104 BID Drug: Placebo Drug: Metformin
Description: KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
Study: NCT01679639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Single dose of aleglitazar in Periods 1, 2, 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Single dose in Periods 1 and 2; multiple doses in Period 3
Study: NCT04331938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regional anesthetic SPG block-bilateral
Description: Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)